Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Licensing deals
Biotech
Sanofi returns to TCEs via $1.2B pact for ph.1-stage trispecific
Sanofi has returned to TCE territory via an agreement to pay $180 million in the near term for a phase 1-stage trispecific from Kali Therapeutics.
James Waldron
Mar 23, 2026 9:27am
Gilead turns down Assembly's ph. 1-stage HBV antiviral
Mar 20, 2026 5:14am
Lilly partner sees weight loss potential in hibernating animals
Mar 19, 2026 10:00am
French biotech pens $128M deal for Kezar protein degrader work
Mar 12, 2026 9:00am
BioNTech's CEO, CMO will depart to set up next-gen mRNA company
Mar 10, 2026 6:30am
Tenacia pens $308M Rapport deal for China rights to epilepsy med
Mar 9, 2026 10:30am
